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Frontotemporal dementia: insights into
the biological underpinnings of disease
through gene co-expression network
analysis
Raffaele Ferrari1*† , Paola Forabosco2†, Jana Vandrovcova1,3, Juan A. Botía1,3, Sebastian Guelfi1,3, Jason D. Warren4,
UK Brain Expression Consortium (UKBEC), Parastoo Momeni5, Michael E. Weale3, Mina Ryten1,3 and John Hardy1
Abstract
Background: In frontotemporal dementia (FTD) there is a critical lack in the understanding of biological and
molecular mechanisms involved in disease pathogenesis. The heterogeneous genetic features associated with
FTD suggest that multiple disease-mechanisms are likely to contribute to the development of this
neurodegenerative condition.
We here present a systems biology approach with the scope of i) shedding light on the biological processes
potentially implicated in the pathogenesis of FTD and ii) identifying novel potential risk factors for FTD. We
performed a gene co-expression network analysis of microarray expression data from 101 individuals without
neurodegenerative diseases to explore regional-specific co-expression patterns in the frontal and temporal
cortices for 12 genes (MAPT, GRN, CHMP2B, CTSC, HLA-DRA, TMEM106B, C9orf72, VCP, UBQLN2, OPTN, TARDBP
and FUS) associated with FTD and we then carried out gene set enrichment and pathway analyses, and
investigated known protein-protein interactors (PPIs) of FTD-genes products.
Results: Gene co-expression networks revealed that several FTD-genes (such as MAPT and GRN, CTSC and
HLA-DRA, TMEM106B, and C9orf72, VCP, UBQLN2 and OPTN) were clustering in modules of relevance in the
frontal and temporal cortices. Functional annotation and pathway analyses of such modules indicated
enrichment for: i) DNA metabolism, i.e. transcription regulation, DNA protection and chromatin remodelling
(MAPT and GRN modules); ii) immune and lysosomal processes (CTSC and HLA-DRA modules), and; iii) protein
meta/catabolism (C9orf72, VCP, UBQLN2 and OPTN, and TMEM106B modules). PPI analysis supported the results
of the functional annotation and pathway analyses.
Conclusions: This work further characterizes known FTD-genes and elaborates on their biological relevance
to disease: not only do we indicate likely impacted regional-specific biological processes driven by FTD-genes
containing modules, but also do we suggest novel potential risk factors among the FTD-genes interactors as
targets for further mechanistic characterization in hypothesis driven cell biology work.
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Background
Frontotemporal dementia (FTD) is the second most
common early onset form of dementia after Alzheimer’s
disease (AD) [1]. Its main clinical presentations (behav-
ioural or language variants) directly reflect atrophy pat-
terns in the frontal or temporal lobes [2]. Sub-cortical
regions are also implicated [3–5] as damage to white
matter (uncinated fasciculus, cingulum bundle and cor-
pus callosum) [6, 7] and deep grey matter structures
(putamen, insula, thalamus and hippocampus) have been
recently reported [8, 9].
The majority of cases show either tau (FTLD-tau) or
ubiquitin/TDP-43 (FTLD-TDP) inclusions (≤40–50 %),
whereas a minority has FUS (≤10 %; FTLD-FUS) or ubi-
quitin/p62 (≤1–2 %; FTLD-UPS) inclusions [10]. Some
(but not all) FTLD-tau cases carry mutations in the
microtubule associated protein tau (MAPT) [11], whilst
FTLD-TDP cases are almost never associated with vari-
ability in the TAR-DNA binding protein 43 (TARDBP),
rather, in progranulin (GRN) and the chromosome 9
open reading frame 72 (C9orf72) genes [3]. Furthermore,
the FTLD-FUS cases do not have a clear genetic compo-
nent, whilst the rare FTLD-UPS cases have been associ-
ated with variability in the charged multivesicular body
protein 2B (CHMP2B) gene [3]. These features suggest
that there is no unidirectional relationship between the
genetics and the molecular pathology of FTD and that
the observed pathological signatures result from com-
plex molecular mechanisms.
To date a handful of genes has been associated with
FTD: besides MAPT, GRN and C9orf72 (found in 2–11 %,
5–11 % and 7–20 % of cases, respectively) [11, 12], genetic
variability in other genes, including CHMP2B, valosin
containing protein (VCP), sequestosome 1 (SQSTM1) and
ubiquilin 2 (UBQLN2), is extremely rare [3, 11]. Further-
more, pathogenic variants in TARDBP and the fused in
sarcoma (FUS) genes seem nearly absent in FTD com-
paratively to ALS or ALS-FTD cases [13]; however, given
that TARDBP and FUS are pathological hallmarks of
FTLD subtypes [10], they likely hold functional relevance
in the pathogenesis of FTD. Finally, recent genome wide
association studies (GWAS) revealed association with
FTD for the modifying factor transmembrane protein
106B (TMEM106B) [14, 15] and two further loci, one con-
taining the RAB38, member RAS oncogene family
(RAB38) and catepsin C (CTSC) genes, and one pointing
to the HLA-locus [16].
In this study we used a systems biology approach
based on gene co-expression network analysis of micro-
array expression data generated from 101 individuals
without neurodegenerative diseases (UK Human Brain
Expression Consortium [UKBEC]) [17] to further inves-
tigate genes and loci associated with FTD and, particu-
larly, to: i) evaluate their co-expression patterns in brain
areas known to be affected in FTD; ii) annotate and
highlight biological processes potentially implicated in
disease mechanisms, and; iii) identify novel potential risk
factors for FTD.
Results
We grouped the FTD-genes into two categories: the
pure (= mainly or exclusively associated with FTD) and
the spectrum (= associated with more than one condi-
tion) genes (Table 1). We evaluated gene expression
levels across different brain regions (frontal and tem-
poral cortices as well as putamen, thalamus, hippocam-
pus, white matter, cerebellum and medulla; see Methods
section for details), assessed co-expression profiles and
performed functional annotation and pathway analyses
for the relevant modules (= we defined ‘relevant mod-
ules’ those modules containing one or more FTD-genes
with hub status [1-q < 0.1] and/or module membership
[MM] values > 0.5; see Methods section for details).
Finally, we investigated whether the observed gene
clustering is supported by known protein-protein
interactors (PPIs) of FTD-genes products to infer the
potential extent of the translation of the regional-
specific co-expression patterns into the protein
domain.
Expression levels in brain
To gain insight into the expression profile of FTD-genes
in brain we searched for expression levels and patterns
online and in our own repositories (Human Brain Atlas
and Braineac, respectively; see Methods section for fur-
ther details). The general, and cross-supportive, outcome
was that all FTD-genes are indeed expressed in brain:
for the pure FTD-genes, MAPT, GRN, CHMP2B, CTSC,
HLA-DRA and TMEM106B showed moderate to high
expression levels across brain tissues throughout the life-
span of an individual, whilst, comparatively, expression
levels for RAB38, BTNL2 and HLA-DRB5 appeared to be
lower. All spectrum FTD-genes, C9orf72, VCP, SQSTM1,
UBQLN2, OPTN, TARDBP and FUS had high expression
levels across brain tissues during development and aging,
and C9orf72,TARDBP and FUS showed exceptionally high
levels in the cerebellum. A focused assessment of the ex-
pression levels and patterns in frontal and temporal corti-
ces revealed that MAPT, UBQLN2, VCP, TMEM106B,
FUS, TARDBP, OPTN, GRN and CHMP2B had high ex-
pression rates, whilst these were comparatively lower for
C9orf72, HLA-DRA and CTSC (Fig. 1a-b).
For a more detailed description and visualization of all
genes’ expression patterns across brain tissues see the
Additional file 1 (pp 1–4) and Additional file 1: Figures
S1-S16 (pp 8–23).
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Weighted gene co-expression network analysis (WGCNA)
We performed the WGCNA with a primary focus on
frontal and temporal cortices, the classically affected
brain areas in FTD. Nevertheless, due to their recent in-
creasing relevance to disease, we also extended the ana-
lysis to other brain regions such as putamen, thalamus,
hippocampus and white matter for both the pure and
spectrum genes, and the cerebellum and medulla for the
spectrum genes only. Assessments on frontal and tem-
poral cortices are presented hereafter and summarized
in Table 2, whilst evaluations on any other brain region
are shown in the Additional file 1 (pp 8–9).
We found four modules of interest in frontal cortex
(Table 2): one included MAPT and GRN, where MAPT
was a hub gene. Another module comprised HLA-DRA
and CTSC: both genes showed high module membership
(MM) values, whilst none was a hub gene. A third mod-
ule displayed TMEM106B that was a hub, and the fourth
included C9orf72, VCP, UBQLN2 and OPTN, where
C9orf72 was a hub. The remaining genes (CHMP2B,
FUS and TARDBP) had poor module assignments
(Table 2).
In the temporal cortex, besides MAPT and GRN that
were assigned to two distinct modules (where neither
one was a hub), we observed similar co-expression pat-
terns as in the case of the frontal cortex (Table 2): HLA-
DRA and CTSC were again co-assigned to the same
module with moderately high MM values (>0.65) but no
hub status; TMEM106B was again a hub within its mod-
ule of membership, and C9orf72, VCP and UBQLN2
were all again assigned to the same module where each
had high MM values, but none was a hub. As seen in
Table 1 FTD-genes analysed in this study
Genes Type of variant Clinical phenotype Pathology Type of association Ref
Pure FTD-genes MAPT exonic/intronic point mutations bvFTD; FTD-17 FTLD-Tau mendelian 3, 11
small/large indels
missense
GRN non-sense bvFTD; PNFA FTLD-TDP 3, 11
missense
frame-shift
large deletions
CHMP2B non-sense FTD3 FTLD-UPS 3, 11
missense
RAB38 unknown bvFTD unknown from GWAS 16
CTSC unknown bvFTD unknown
BTNL2 unknown bvFTD; PNFA; SD unknown
HLA-DRA unknown bvFTD; PNFA; SD unknown
HLA-DRB5 unknown bvFTD; PNFA; SD unknown
TMEM106B unknown FTD FTLD-TDP 14
Spectrum FTD-genes C9orf72 expansion ALS; ALS-FTD FTLD-TDP mendelian 12, 13
VCP missense IBMPFD; ALS; FTD FTLD-TDP 3, 11, 12
SQSTM1 non-sense PBD; ALS; FTD FTLD-TDP 3, 11, 12
missense
UBQLN2 non-sense MS; ALS; FTD FTLD-TDP
missense
OPTN non-sense PDB; ALS-FTD FTLD-TDP
missense
TDP-43 missense ALS; ALS-FTD FTLD-TDP
FUS missense ALS; ALS-FTD FTLD-FUS
frame-shift
indel
The FTD-genes used in our analysis were divided into two groups: the pure and the spectrum genes. For each gene, the associated genetic variability, as well as
the associated clinical and pathological features are summarized
bvFTD behavioural variant FTD, FTD-17 frontotemporal dementia linked to chromosome 17, PNFA progressive non-fluent aphasia, FTD3 frontotemporal dementia
linked to chromosome 3, SD semantic dementia, ALS amyotrophic lateral sclerosis, IBMPFD Inclusion body myopathy with early-onset Paget disease and frontotemporal
dementia, PBD Paget’s disease of bone, MS multiple sclerosis
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the frontal cortex, CHMP2B, OPTN, FUS and TARDBP
did not hold major relevance in temporal cortex mod-
ules (Table 2).
Enrichment analysis identified the modules including
HLA-DRA and CTSC, and C9orf72, VCP, UBQLN2 (and
OPTN) as significantly enriched for FTD-genes (p < 0.05;
Table 2). To visualize these as well as the interconnec-
tion networks of MAPT, GRN and TMEM106B we gen-
erated Figs. 2, 3, 4 and 5 for which the main nodes are
listed in Additional file 2: Table S20.
Since the FTD-genes distributed rather similarly
within the modules in frontal and temporal cortex, we
sought to further investigate the clustering across other
brain tissues. We discovered moderate to high quantita-
tive overlap (i.e. number of shared genes) between
frontal and temporal cortex modules as shown and ex-
plained in the Additional file 1: Figure S17 (p 26). Also, we
verified through composite Z-summary preservation sta-
tistics that the modules containing FTD-genes in frontal
and temporal cortex were, for the most, preserved across
other brain regions (Additional file 1, p 27).
Replication
In order to replicate and support our findings, we
assessed the reproducibility of the frontal cortex net-
works as a ‘whole ‘and ‘module by module’, using an
Fig. 1 Expression levels. Expression levels of the FTD-genes considered in the network analysis in frontal cortex (a) and temporal cortex (b). FUS
here was represented by Affymetrix transcript ID 3656904
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Table 2 Module assignments for FTD-genes in frontal and temporal cortex
FTD genes Affymetrix ID type Frontal cortex Temporal cortex
module Sz (n) MM 1-q module Sz (n) MM 1-q
MAPT 3723687 pure black 791 0.83 0.03 lightyellow 210 0.67 0.31
GRN 3722917 0.66 0.34 cyan 276 0.56 0.51
CHMP2B 2631845 darkolivegreen 63 0.76 0.48 green 1439 0.53 0.49
HLA-DRA 2903189 darkred (p = 0.0046) 141 0.8 0.23 lightcyan (p = 0.0139) 250 0.66 0.51
CTSC 3385769 0.73 0.5 0.69 0.47
TMEM106B 2990342 red 925 0.78 0.04 darkturquoise 164 0.86 0.01
C9orf72 3202421 spectrum purple (p = 0.0226) 1559 0.74 0.1 purple (p = 0.0206) 830 0.75 0.14
VCP 3204404 0.68 0.19 0.71 0.24
UBQLN2 3978999 0.55 0.45 0.63 0.45
OPTN 3235726 0.59 0.38 grey60 220 0.53 0.8
FUS 3656904 lightcyan 209 0.58 0.61 midnightblue 268 0.64 0.31
FUS 3656950 blue 3329 0.31 0.69 pink 2979 0.39 0.58
FUS 3656954 0.5 0.38 magenta 1000 0.44 0.72
TDP-43 2320048 turquoise 4759 0.22 0.89 0.53 0.54
The FTD-genes (with corresponding Affymetrix IDs) are listed. Co-expression modules for the FTD-genes and their relevance within modules are displayed. Sz = size, i.e.
number of transcripts contained in the module; MM=module membership; 1-q = 1-quantile of MM. The bolded parts highlight the fact that WGCNA indicated the fol-
lowing: 1) (MAPT and GRN), (HLA-DRA and CTSC), (C9orf72, VCP, UBQLN2 and OPTN) and (2 FUS) transcripts were respectively present in the same modules in frontal cor-
tex, and; 2) (HLA-DRA and CTSC), (C9orf72, VCP and UBQLN2) and (FUS and TARDBP) transcripts were respectively present in the same modules in temporal cortex. The
modules containing (HLA-DRA and CTSC) and (C9orf72, VCP, UBQLN2 [and OPTN]) were significantly enriched for FTD transcripts
Fig. 2 Network visualisation of genes of the black module in frontal cortex. VisANT plot shows genes (blue, gene names in bold) directly connected
with a topological overlap measure TOM> 0.10 to FTD-genes, MAPT and GRN (purple, gene names in bold). All such genes are important hubs within
this module whose connections are based on TOM> 0.115
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Fig. 3 Network visualisation of genes of the darkred module in frontal cortex. VisANT plot shows genes (blue, gene names in bold) directly connected
to FTD-genes, CTSC and HLA-DRA (purple, gene names in bold). All such genes are important hubs within this module and all connections shown here
are based on TOM >0.165
Fig. 4 Network visualisation of genes of the red module in frontal cortex. VisANT plot shows genes (blue, gene names in bold) directly connected to
FTD gene, TMEM106B (purple, gene name in bold). All such genes are important hubs within this module and all connections shown here are based
on TOM> 0.1
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independent and well established dataset [18]. Our
WGCNA TOM (topological overlap measure) was sig-
nificantly reproduced in the WGCNA TOM matrix con-
structed from the Colauntoni dataset (p-value = 1x10-3),
thus supporting robust correlation between the two
datasets. Further, through the Z-summary preservation
estimate we noted that 10 of our frontal cortex modules
showed strong evidence of preservation (Z-summary > 10)
in the Colauntoni dataset, and 30 had moderate to high
preservation levels (2 < Z-summary < 10). Particularly,
the Z scores for the modules of interest – based on
Table 2 – were all supportive of preservation: red
(TMEM106B) module (Z = 3.61), black (MAPT and GRN)
module (Z = 7.15), purple (C9orf72, VCP, UBQLN2
and OPTN) module (Z = 9.28) and darkred (HLA-DRA
and CTSC) module (Z = 29.73) (Fig. 6).
Functional annotation and pathway analyses
To gain insight into their biological significance, we anno-
tated genes in the network assessing gene ontology (GO)
terms for biological processes (BPs), cellular components
(CCs) and molecular functions (MFs) and performed
pathways analyses for the relevant FTD-modules. The
analyses of modules in frontal and temporal cortices
(based on Table 2) are presented hereafter, whilst those of
other brain tissues are summarized in the Additional file 1
(pp 8–9) and Additional file 2: Table S19.
In frontal cortex, significant GO terms associated with
the module containing MAPT and GRN indicated tran-
scription processes and chromatin metabolism with a
particular involvement of the histone methyltransferase
complex as well as transcription factor and nucleic acid
binding activities (Table 3a); such annotations were sup-
ported by pathways analysis that also indicated the me-
tabolism of the chromatin. Evaluation of the list of
predefined enrichment for brain terms in WGCNA (see
Additional file 1, pp 28–29) revealed significant overlap
with the green M10 module associated with Glutamater-
gic Synaptic Function in neurons identified in [19]
(Table 3a). In temporal cortex, the MAPT-containing
module was enriched for transcription processes
(Table 3b and Additional file 1, p 5), whereas the GRN-
containing module for broad biology of membrane-
bounded organelle (Table 3b and Additional file 1, p 5).
Here, the list of predefined enrichment for brain terms in
WGCNA showed significant overlap particularly with the
green M10 module associated with Glutamatergic Synap-
tic Function in neurons identified in [19] for both mod-
ules. The complete list of GO terms associated with the
modules including MAPT and GRN in frontal and tem-
poral cortices can be found in Additional file 2: Tables S2,
S6 and S7.
Functional annotation analysis for the modules com-
prising HLA-DRA and CTSC indicated modulation of
the immune responses via the innate and adaptive
Fig. 5 Network visualisation of genes of the purple module in frontal cortex. VisANT plot shows genes (blue, gene names in bold) directly connected
with a topological overlap measure TOM> 0.08 to FTD-genes, OPTN, UBQLN2, VCP and C9orf72 (purple, gene names in bold). All such genes are import-
ant hubs within this module whose remaining connections are based on TOM >0.11
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systems in both the frontal (Table 3a) and temporal cor-
tices (Table 3b). Pathways analysis revealed implication
of immune system, phagosomes, antigen processing and
presentation, interferon gamma- and cytokine-signalling,
and lysosomes (Table 3a and b, and Additional file 2:
Table S17), and the list of predefined enrichment for
brain terms in WGCNA suggested enrichment for
microglia markers given significant overlap with pink
M10 and purple M4 Microglia (Type1) modules identi-
fied in [17, 19, 20] (Table 3a and b). The complete list of
GO terms associated with the modules containing HLA-
DRA and CTSC in the frontal and temporal cortices can
be found in Additional file 2: Tables S4 and S9.
For the modules including TMEM106B, we noted GO
terms indicating protein metabolic processes exerted
through catalytic complexes in frontal cortex (Table 3a),
whereas terms were rather general in temporal cortex
(Table 3b). Pathway analysis pointed to chromatin me-
tabolism for the frontal cortex (Table 3a) and protein
processing in endoplasmic reticulum (ER) for the tem-
poral cortex (Table 3b). The list of predefined enrich-
ment for brain terms in WGCNA indicated that both
the TMEM106B-containing modules in frontal and tem-
poral cortex held overlapping features with the yellow
M18 (enriched for protein metabolism) and the blue
M16 Neuron modules identified in [19] (Table 3a). In
addition, there was further overlap – for the frontal cor-
tex module only – with the turquoise M14 Nucleus,
Oligodendrocyte probable and brown pyramidal Neu-
rons Layer5/basolateral Amygdala modules found in
[20–23] (Table 3a), indicating that the TMEM106B pro-
tein most probably takes part in different biological
Fig. 6 Z-summary graph. The ‘Z-summary preservation estimate’ estimates how interaction patterns of genes within modules one dataset are
preserved in another dataset, i.e. it estimates how the genes which cluster together in the reference tissue maintain that clustering in the other
dataset. The Z preservation summary is a mean of both estimates. The colour codes are those of reference, i.e. from our own dataset
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Table 3 Summary of most relevant GO terms, pathways and brain lists annotation for relevant modules in frontal cortex (a) and temporal
cortex (b)
FTD gene MM 1-q type module sz G:Profiler Annotation (GO terms &
Pathways analyses)
WGCNA – Brain lists
a.
MAPT 0.83 0.03 pure black 791 BP: Transcription, DNA-templated
(p=2.77x10-5); RNA biosynthetic
process (p=3.17x10-5); Chromatin
modification (p=9.45x10-5)
CC: Nuclear lumen (p=2.81x10-13);
Histone methyltransferase complex
(p=3.2x10-7)
MF: Transcription factor binding
transcription factor activity (p=6.26x10-6);
Nucleic acid binding (p=7.19x10-6)c3v1234
Pathways: Chromatin organization
and Chromatin modifying enzymes
(p=4.84x10-3ZX)
Glutamatergic Synaptic Function
(CTX) (p=1.36x10-7)
GRN 0.66 0.34
HLA-DRA 0.8 0.23 darkred 141 BP: Immune system process (p=1.39x10-31);
Defense response (p=5.23x10-29); Innate
immune response (p=2.51x10-19);
Adaptive immune response (p=1.71x10-7);
Phagocytosis (p=6.2x10-3)
CC: MHC class II
protein complex (p=1.17x10-7); Lysosome
(p=7.69x10-5); Lytic vacuole (p=7.69x10-5)
MF: Receptor activity (p=1.88x10-8);
Signal transducer activity (p=6.45x10-6)
Pathways: Immune system (p=4.8x10-21);
Phagosome (p=6.69 x 10-12); Adaptive
immune system (p=5.08 x 10-10);
Cytokine signaling in immune system
(p=2.63 x 10-7); Lysosome (p=4.89 x 10-2)
Microglia (Type1) (HumanMeta) (p=1.53x
10-84)Microglia (Type1) (CTX) (p=7.01x
10-31)Up In Frontal Cortex (Early AD)
(p=2.96x10-19)
CTSC 0.73 0.5
TMEM106B 0.78 0.04 red 925 BP: Cellular protein metabolic process
(p=3.84x10-5)
CC: Nuclear lumen (p=9.36x10-6);
Catalytic complex (p=1.36x10-2)
MF: Ligase activity (p=1.96x10-2)
Pathways: Chromatin organization
(p=1.1x10-2); HATs acetylate histones
(p=1.3 x 10-2); HDACs deacetylate
histones (p=3.2 x 10-2)
Protein metabolism (CTX) (p=7.57x10-10)
Neuron (CTX) (p=4.83x10-5)Nucleus
(HumanMeta) (p=1.09x10-5)
Oligodendrocyte probable (Cahoy)
(p=2.42x10-5)Brown pyramidal Neurons
Layer5/basolateral Amygdala (Sugino/
Winden) (p=2.80x10-5)
C9orf72 0.74 0.1 spectrum purple 1559 BP: Modification-dependent macromolecule
catabolic process (p=3.9x10-7); Ubiquitin-
dependent protein catabolic process
(p=1.08x10-6); Proteolysis involved in cellular
protein catabolic process (p=1.72x10-6)
CC: Cytoplasm (p=2.95x10-14);
Mitochondrion (p=2.4x10-12); Proteasome
complex (p=2.81x10-4)
MF: Catalytic activity (p=3.55x10-4)
Pathways: Protein processing in endoplasmic
reticulum (p=1.01x10-5); Mitochondrial
translation (p=2.28x10-3)
Neuron (CTX) (p=8.76x10-27)Neuron
(HumanMeta) (p=9.02x10-25)Mitochondrion
(p=1.63x10-19)Post Synaptic Density
proteins (Bayes) (p=8.73x10-18)
VCP 0.68 0.19
UBQLN2 0.55 0.45
OPTN 0.59 0.38
b.
MAPT 0.67 0.31 pure lightyellow 210 BP: Transcription from RNA polymerase II
promoter (p=1.23x10-4)CC: Nucleus
(p=3.69x10-5)
MF: Protein binding (p=2.93x10-4);
Transcription factor binding (p=1.42x10-2)
Pathways: RNA Polymerase II Transcription
Elongation (p=4.21x10-2)
Glutamatergic Synaptic Function
(CTX) (p=3.79x10-5)
GRN 0.56 0.51 cyan 276 CC: intracellular membrane-bounded
organelle (p=7.56x10-3)
Pathways: Signaling by Wnt
(p=7.61x10-3); Lysosome (p=1.21x10-2)
Glutamatergic Synaptic Function (CTX)
(p=9.89x10-8)Mitochondria (HumanMeta)
(p=1.74 x10-5)
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processes in diverse brain areas. The complete list of
GO terms associated with the modules including
TMEM106B in frontal and temporal cortices can be
found in Additional file 2: Tables S5 and S10.
Functional annotation analysis for the module contain-
ing C9orf72,VCP, UBQLN2 (and OPTN) in the frontal and
temporal cortices pointed to ubiquitin-mediated protein
catabolic process entailing proteasome and proteolysis
activities, and to ER-associated ubiquitin-dependent pro-
tein catabolic process and endosomal transport (Table 3a
and b). Pathways analysis hinted to protein processing in
ER and also supported the ubiquitin-dependent degrad-
ation of proteins and the proteasome biology (Table 3a
and b, and Additional file 2: Table S17). In addition, there
was significant overlap with numerous WGCNA lists par-
ticularly pointing to the blue M16 Neuron module identi-
fied in [19] (Table 3a and b). The complete list of GO
terms associated with the modules including C9orf72,VCP,
UBQLN2 (and OPTN) in the frontal and temporal cortices
can be found in Additional file 2: Tables S11 and S14.
For completeness, we also performed functional annota-
tion and pathway analysis for the genes with poor module
assignments (CHMP2B, FUS and TARDBP; Table 2):
results are briefly detailed in the Additional file 1, pp 4–8
and in Additional file 2: Table S19.
Protein-protein interactors (PPIs) of FTD-genes
We sought to verify whether genes clustering together
with FTD-genes in the relevant FTD-modules are found
to interact at the protein level with the FTD-genes prod-
ucts. We searched for known PPIs of MAPT, GRN,
HLA-DRA, CTSC, TMEM106B, C9orf72, VCP, UBQLN2
and OPTN (Additional file 2: Table S21a and b), and
assessed any nominal overlap with genes co-clustering in
modules containing the FTD-genes in the frontal and
temporal cortices. Only for TMEM106B no nominal
overlap between PPIs and related transcripts was seen.
Among the MAPT-PPIs, MARK2 (MAP/microtubule
affinity-regulating kinase 2), MARK4 (MAP/microtubule
affinity-regulating kinase 4) and EP300 (E1A binding
protein p300) were assigned to the module containing
MAPT in frontal cortex. Here, MARK2 was a hub, whilst
MARK4 and EP300 were among the top ~15 % inter-
active genes (Additional file 2: Table S1a). MARK2 and
MARK4 encode kinases that target proteins involved in
stabilizing the microtubules, while EP300 encodes an
acetyltransferase; of note, MARK2 and EP300 co-
clustered with MAPT within GO terms pointing to the
nucleus and indicated features such as DNA-, RNA- and
protein-binding (MARK2), and transferase/catalitic com-
plexes and nuclear chromatin (EP300) in frontal cortex
(Additional file 2: Table S2). Conversely, MARK2, EP300
and AKT1 (v-akt murine thymoma viral oncogene
homolog 1) were assigned to the MAPT-containing
module in temporal cortex (Additional file 2: Table S6),
where MARK2 was a hub (Additional file 2: Table S1b).
The protein kinase AKT1 is a critical mediator of growth
factor-induced neuronal survival in the developing
Table 3 Summary of most relevant GO terms, pathways and brain lists annotation for relevant modules in frontal cortex (a) and temporal
cortex (b) (Continued)
HLA-DRA 0.66 0.51 lightcyan 250 BP: Immune system process
(p=1.89x10-37);
Defense response (p=1.51x10-32);
Phagocytosis (p=1.39x10-5)
CC: MHC class II protein complex
(p=3.02x10-6); Lysosome (p=5.43x10-5);
Lytic vacuole (p=5.43x10-5)
MF: Receptor activity (p=4.41x10-10)
Pathways: Immune system (p=8x10-22);
Phagosome (p=7.2x10-13); Innate immune
system (p=1x10-11); Adaptive immune
system (p=2.56x10-9)
Microglia (Type1) (HumanMeta)
(p=1.53x10-84)Microglia (Type1)
(CTX) (p=1.08x10-30)
Up In Frontal Cortex
(EarlyAD) (p=7.85x10-19)
CTSC 0.69 0.47
TMEM106B 0.86 0.01 darkturquoise 164 CC: Cytoplasm (p=2.8x10-5); Nucleus
(p=2.49x10-4)
Pathways: Protein processing in
endoplasmic reticulum (p=4.86x10-5)
Nucleus (CTX) (p=3.67x10-9)
Metabolism (CTX) (p=3.48x10-5)
C9orf72 0.75 0.14 spectrum purple 830 BP: Proteolysis involved in cellular protein
catabolic process (p=1.81x10-8); Ubiquitin-
dependent protein catabolic process
(p=3.04x10-8); Protein catabolic process
(p=1.87x10-6)CC: Cytoplasm (p=1.28x10-12);
Proteasome complex (p=1.16x10-5);
Endoplasmic reticulum membrane
(p=5.21x10-3)
MF: Catalytic activity (p=1.08x10-4)
Pathways: Protein processing in
endoplasmic reticulum (p=5.25x10-6)
Neuron (CTX) (p=9.29x10-24)
Neuron (HumanMeta) (p=6.96x10-11)
Post Synaptic Density proteins
(Bayes) (p=4.34x10-5)
VCP 0.71 0.24
UBQLN2 0.63 0.45
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nervous system. These 3 genes were found in GO terms
pointing to the nucleus, together with MAPT, and tran-
scription or RNA metabolic processes (Additional file 2:
Table S6).
Among the GRN-PPIs, ATN1 (atrophin 1), SGTA
(small glutamine-rich tetratricopeptide repeat (TPR)-
containing, alpha), CRKL (v-crk avian sarcoma virus
CT10 oncogene homolog-like) and TLE3 (transducin-
like enhancer of split 3) were assigned to the module
containing GRN in frontal cortex. Here, ATN1, that
encodes atrophin 1, a conserved transcriptional co-
repressor [24] and whose expansions have been associ-
ated with neurodegeneration [25], was a hub (Additional
file 2: Table S1a). SGTA encodes a small glutamine-rich
tetratricopeptide repeat (TPR)-containing, alpha that
might be involved in neuronal apoptotic processes [26].
CRKL encodes an oncogene and seems pleiotropic in
physiologic signalling [27], whilst TLE3 is a transcrip-
tional co-repressor. ATN1 and TLE3 were found in
gene lists indicating GO terms pointing to the nucleus
and transcription related processes (Additional file 2:
Table S2). No relevant functional annotations were
available for SGTA, whereas CRKL appeared to be involved
in DNA- and RNA-binding (with GRN; Additional file 2:
Table S2). Conversely, TLE3 and CRKL were assigned to
the GRN-containing module in temporal cortex and
annotation analysis indicated GO terms involving the
biology of membrane-bounded organelle (with GRN;
Additional file 2: Table S7).
There was nominal overlap between HLA-DRA-PPIs
and relative genes (Additional file 2: Table S21a),
whereas there was none for CTSC. HLA-DMB (major
histocompatibility complex, class II, DM beta), HLA-
DMA (major histocompatibility complex, class II, DM
alpha) and CD74 (CD74 molecule, major histocompati-
bility complex, class II invariant chain) were present in
both modules containing HLA-DRA in the frontal
(Additional file 2: Table S4) and temporal cortex
(Additional file 2: Table S9). HLA-DMA and HLA-DMB
encode the major histocompatibility complex, class II,
DM alpha and beta, which is anchored in the membrane
of intracellular vesicles and plays a central role in the
peptide loading of MHC class II molecules [28]. CD74
encodes a chaperone that regulates antigen presentation
during immune response. HLA-DMB, HLA-DMA and
CD74 were included within all or most of the GO terms
indicated by our functional annotation analysis together
with HLA-DRA and/or CTSC (Additional file 2: Tables S4
and S9).
A large number of PPIs of VCP, UBQLN2 and OPTN
nominally overlapped with the genes co-expressed with
C9orf72,VCP, UBQLN2 (and OPTN) in the relative mod-
ules in the frontal and temporal cortices; conversely, this
was the case only for a few of the C9orf72-PPIs
(Additional file 2: Table S21b). We found up to 10 PPIs
of VCP that were also hubs in frontal and/or temporal
cortex (Additional file 2: Table S1a and b): CUL2 (cullin
2), UBQLN1 (ubiquilin 1), NF1 (neurofibromin 1), NIPS-
NAP1 (nipsnap homolog 1), BTRC (beta-transducin re-
peat containing E3 ubiquitin protein ligase), ARFGEF2
(ADP ribosylation factor guanine nucleotide exchange
factor 2), COPS3 (COP9 signalosome subunit 3), PLAA
(phospholipase A2-activating protein), CLTA (clathrin,
light chain A) and ANXA7 (annexin A7); all such pro-
teins are involved, mainly, in either protein catabolic or
intracellular vesicle transport processes (Table 4). For
UBQLN2 we found 5 PPIs that were also hubs in the
frontal and/or temporal cortex (Additional file 2: Table
S1a and b): UBQLN1, SEC23A (Sec23 homolog A,
COPII coat complex component), USP9X (ubiquitin spe-
cific peptidase 9, X-linked), STAM (signal transducing
adaptor molecule) and HSPA13 (heat shock protein fam-
ily A (Hsp70) member 13); these are, overall, involved in
protein degradation and ER-Golgi protein transport pro-
cesses (Table 4). In the case of OPTN we counted two
PPIs that were also hubs (Additional file 2: Table S1a
and b): RAB11A (RAB11A, member RAS oncogene fam-
ily) and RTN3 (reticulon 3), involved in protein transport
and modulation of ß-amyloid production, respectively
(Table 4). Finally, for C9orf72 we found only three PPIs
(none of which was a hub): APP (amyloid beta (A4)
precursor protein), ELAVL1 (ELAV like RNA binding
protein 1) and EIF2B2 (eukaryotic translation initiation
factor 2B subunit beta), linking C9orf72, provided fur-
ther evidence, to the ß-amyloid production, RNA metab-
olism and protein synthesis, respectively (Table 4).
Interestingly, we noticed that all genes mentioned above
(and PPI interactors of VCP, UBQLN2, OPTN or
C9orf72) were included together with the spectrum
FTD-genes in the gene lists supporting GO terms indi-
cating functions pointing to protein catabolism pathways
and cytoplasmic protein transport and/or vesicle traf-
ficking as highlighted in Additional file 2: Tables S11
and/or S14.
Taken all together, the module assignments in the
frontal and temporal cortices as well as the functional
annotation, pathways and PPIs analyses provide not only
a more comprehensive picture of the potential biological
and cellular mechanisms involved in the development of
FTD but also an enlarged domain of novel potential
genetic or functional risk factors associated with FTD
(that are comprehensively summarized in Table 4).
Discussion
In this study we used a systems biology approach based
on gene co-expression network analysis of microarray
expression data to investigate genes known to be associ-
ated with FTD. After a general assessment of their
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Table 4 Novel potential risk factors in FTD
Novel potential
risk factor
Interactor of Function Topography Evidence
KHSRP MAPT, GRN involved in alternative pre-mRNA splicing and mRNA localization FCTX WGCNA + VisANT
SF3A1 GRN
CREBBP MAPT acetyltransferase involved in chromatin remodelling and transcriptional
activation/regulation
MLL2 methyl-transferase involved in chromatin remodelling
SRCAP involved in transcriptional activation/regulation
HCFC1
MARK2 MAPT kinase involved in stabilizing the microtubules and tau’s
phosphorylation
FCTX,
TCXT
WGCNA + PPI
MARK4 FCTX
EP300 acetyltransferase involved in tau’s acetylation FCTX,
TCXT
AKT1 kinase involved in growth factor-induced neuronal survival in the
developing nervous system
TCTX
ATN1 GRN transcriptional co-repressor factor FCTX
SGTA involved in neuronal apoptotic processes
CRKL oncogene pleiotropic in physiologic signalling FCTX,
TCXT
TLE3 transcriptional co-repressor factor
CYBB HLA-DRA, CTSC critical component of the oxidase system of phagocytes FCTX WGCNA + VisANT
DOCK8 involved in neuronal development and immune cells shaping
HLA-DMA HLA-DRA transmembrane protein of intracellular vesicles involved in peptide
loading of MHC class II molecules
FCTX,
TCXT
WGCNA + PPI
HLA-DMB
CD74 chaperone involved in antigen presentation during immune response
COPB2 TMEM106B involved in Golgi budding and vesicular trafficking FCTX WGCNA + VisANT
SERINC1 involved in lipid biosynthesis in neurons at the ER level
NRD1 metalloprotease with potential neuropathogenic role
TTC37 protein-protein interactor with chaperone activity
CAND1 C9orf72, VCP involved in ubiquitin ligase network FCTX WGCNA + VisANT
PSMD12 C9orf72 subunit of a multi-catalytic proteinase complex
MYCBP2 C9orf72 E3 ubiquitin protein ligase (alias)
ATL1 C9orf72, VCP involved in axonal maintenance
UBQLN1 VCP ubiquitin-like protein which links the ubiquitination and
proteasome machineries
APP C9orf72 cell surface receptor and transmembrane precursor protein cleaved by
secretases into different peptides: some of these can bind to the
acetyltransferase complex (APBB1/TIP60) to promote transcriptional
activation; others form the protein basis of the amyloid plaques
FCTX,
TCTX
WGCNA + PPI
ELAVL1 RNA-binding protein that contain several RNA recognition motifs, and
selectively bind AU-rich elements (AREs) found in the 3' untranslated
regions of mRNAs. AREs signal degradation of mRNAs as a means to
regulate gene expression; the ELAVL family stabilizes ARE-
containing mRNAs
EIF2B2 beta subunit of eukaryotic initiation factor-2B (EIF2B). EIF2B is involved
in protein synthesis and exchanges GDP and GTP for its activation
and deactivation
FCTX
CUL2 VCP Cullins are a family of NEDD8 targets important in the stabilization
and degradation of proteins
FCTX,
TCTX
UBQLN1 part of the ubiquitination machinery of the proteasome to affect
in vivo protein degradation
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expression levels in different brain regions, we particu-
larly evaluated co-expression patterns in brain areas
known to be affected in FTD with a major focus on the
frontal and temporal cortices and inferred biological
processes potentially implicated in the pathogenesis of
FTD. We also sought to identify novel potential risk
factors for FTD.
Prior to putting our results into context, a number of
limitations that apply to this work need to be acknowl-
edged: i) although the prevalence of FTD is almost equal
among males and females [3], data available for this
study were generated mainly in male individuals (78/
101); ii) the disease generally manifests between mid 50s
to early 60s years of age and, although expression data
were corrected for individual effects including sex and
age at death, the study cohort had a mean age of 50 years
(ranging from 16 to 83 years); iii) besides that there is
no golden standard approach or pipeline in systems biol-
ogy studies, it is important to note that data supporting
functional annotation and enrichment analyses pre-
sented here are based on the current literature (i.e.
focused on a restricted number of targets or pathways)
and that data mining has been manually curated or
generated by semantic associations, thus some or novel
interactions might be overlooked.
The data on expression levels across brain tissues indi-
cated that MAPT, GRN, CHMP2B, CTSC, HLA-DRA,
TMEM106B, C9orf72, VCP, SQSTM1, UBQLN2, OPTN,
TARDBP and FUS are all robustly expressed in (thus
clearly hold relevance for the biology of ) the aging brain.
Table 4 Novel potential risk factors in FTD (Continued)
NF1 negative regulator of the ras signal transduction pathway (control such
processes as actin cytoskeletal integrity, proliferation, differentiation,
cell adhesion, apoptosis and cell migration)
NIPSNAP1 family of proteins involved in vesicular transport FCTX
BTRC constitutes one of the four subunits of ubiquitin protein ligase complex
called SCFs (SKP1-cullin-F-box) that function in phosphorylation-
dependent ubiquitination
FCTX,
TCTX
ARFGEF2 plays an important role in intracellular vesicular trafficking;
involved in Golgi transport
FCTX
COPS3 kinase activity that phosphorylates regulators involved in
signal transduction
PLAA activation of protein kinase C (PKC) and PKC-dependent responses
(in response to inflammatory mediators and release during apoptosis)
CLTA part of structural component of the lattice-type cytoplasmic face of
coated pits and vesicles which entrap specific macromolecules
during receptor-mediated endocytosis with regulatory function
ANXA7 a membrane binding protein with diverse properties (voltage-sensitive
calcium channel activity, ion selectivity and membrane fusion)
UBQLN1 UBQLN2 part of the ubiquitination machinery of the proteasome to affect in
vivo protein degradation
FCTX,
TCTX
SEC23A suggested to play a role in the ER-Golgi protein trafficking
USP9X protein similar to ubiquitin-specific proteases
STAM mediates downstream signaling of cytokine receptors and also play
a role in ER to Golgi trafficking
HSPA13 member of the heat shock protein 70 family and is found associated
with microsomes. Members of this protein family play a role in the
processing of cytosolic and secretory proteins, as well as in the
removal of denatured or incorrectly-folded proteins
RAB11A OPTN involvedin constitutive, regulated secretory pathways and
protein transport
FCTX
RTN3 expressed in neuroendocrine tissues: interacts with and modulates the
activity of beta-amyloid converting enzyme 1 (BACE1), and the
production of amyloid-beta
Each novel potential risk factor is listed along with the interacting FTD-gene(s). The evidence of interaction is primarily defined by our WGCNA data that assigned
each transcript to a module containing one (or more) FTD-gene(s) in frontal and/or temporal cortex. The nomenclature (WGCNA + VisANT) indicates that the novel
potential risk factor is chosen because of its hub status and its interaction with FTD-gene(s) based on topological overlap measure (TOM) > 0.10 (see also Figs. 2, 3,
4 and 5). The nomenclature (WGCNA + PPI) indicates that the novel potential risk factor is chosen based on nominal overlap between interactive transcript(s) and
protein(s). The potential risk factors belonging to the latter category are bolded as an indication that the WGCNA + PPI combination could be a strong indicator
for regional-specific impacted functional networks. The main known function(s) of each novel potential genetic and/or functional risk factor is included in the
central column. FCTX = frontal cortex; TCTX = temporal cortex
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Comparatively, by showing rather lower expression rates,
it is a possibility that RAB38, BTNL2 and HLA-DRB5
might rather represent sensitive cellular markers and
sudden changes in their expression levels might impact
cellular homeostasis.
The current work revealed that MAPT–GRN, HLA-
DRA–CTSC, TMEM106B and C9orf72–VCP–UBQLN2–
OPTN clustered in interesting modules in the frontal
and/or temporal cortex and that, particularly on the
basis of functional annotation and pathway analyses,
three main biological processes with a direct relation to
FTD-genes hold relevance to the pathogenesis of FTD: i)
DNA & chromatin biology; ii) immune & lysosomal
processes, and; iii) protein meta/catabolism.
The first biological process, i.e. DNA and chromatin
implication (including transcription [i.e. RNA biosyn-
thesis and gene expression] and chromatin remodelling),
was defined by modules containing MAPT (and GRN),
and appeared to be specific to neurons in the frontotem-
poral cortices, and the putamen (Fig. 7). This is, overall,
a relatively novel concept in FTD, and it is noteworthy
to appreciate that genes responsible for alternative pre-
mRNA splicing and mRNA localization (KHSRP [KH-
type splicing regulatory protein] and SF3A1 [splicing
factor 3a, subunit 1]), chromatin remodelling such as
acetyl- (CREBBP [CREB binding protein]) and methyl-
transferases (MLL2 [lysine (K)-specific methyltransfer-
ase]), and transcriptional activation/regulation (CREBBP,
SRCAP [Snf2-related CREBBP activator protein] and
HCFC1 [host cell factor C1]) were strong hubs and
highly co-expressed and interconnected with MAPT
and/or GRN (Additional file 2: Table S1a and S20). Even
more importantly, we noted that genes such as MARK2,
MARK4, EP300 and AKT1, and ATN1, SGTA, CRKL and
TLE3 not only were co-expressed with MAPT and GRN,
respectively, in frontal cortex and/or temporal cortex,
but also that they are PPIs of either tau or GRN pro-
teins: these could be novel functional risk factors to be
further investigated in the functional environment. Par-
ticularly, MARK2, MARK4, AKT1 and EP300 influence
Tau’s phosphorylation and acetylation [29–32], whilst
ATN1 and TLE3 regulate transcription, and CRKL is
involved in DNA-binding processes. If the protein inter-
actors of GRN support transcription related processes,
those of MAPT appear to directly influence tau’s activ-
ities and function, fostering some intriguing consi-
derations. Tau is classically known for binding and
stabilizing microtubules in neuronal soma and axons
[33], but it also localizes in their nucleus [34]. Recent
data showed that when DNA damage occurs, tau is de-
phosphorylated and imported into the nucleus to exert
protective effect in stressed neurons [35, 36]. Conversely,
Fig. 7 Scheme of the regional distribution of the FTD-genes and associated annotated biological processes or functions. Rectangles contain FTD-
gene(s) and their main associated regional-specific biological process. Each colour indicates a particular biological process. Font size differs based
on statistics associated with the transcript(s) within their assigned modules. Font 10 = hub (1-q < 0.1) + MM > 0.7; Font 8 = 1-q > 0.1 + MM> 0.6,
and; Font 6 = 1-q > 0.1 + MM≤ 0.6. If multiple transcripts belong to a module, at least 1 has values that justify the font size
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acetylation was suggested to affect tau’s phosphorylation
patterns leading to early events of tau pathology [29]. All
this suggests that MAPT-phosphorylation dynamics are
highly sensitive and critical in regulating not only i) mi-
crotubules homeostasis and ii) aberrant cytoplasmic ac-
cumulation of hyper-phosphorylated tau, but also iii)
tau’s shuttling between the cytoplasm and the nucleus.
Impairment of the latter might have detrimental down-
stream effect on DNA protection. Our data support tau’s
involvement in DNA binding and given evidence for its
involvement in DNA protection [35], it follows that tau
must hold relevance in protecting neurons from apop-
tosis and/or aberrant transcription events, thus support-
ing neuronal longevity. Finally, our data also indicate
that tau’s RNA might be target of genes regulating
mRNA splicing and gene expression and determining
which tau isoform is being expressed; this supports the
hypothesis that aberrant regulation of tau splicing/ex-
pression might contribute to tau pathology [31]. With
this work we are now highlighting potential effectors of
tau’s splicing/expression regulation such as the above
mentioned KHSRP and SF3A1 (which are splicing regu-
latory protein), and CREBBP, SRCAP and HCFC1 (which
are transcriptional activators/regulators); these factors
should be further investigated in the cell-biology setting.
The second biological process was defined by HLA-
DRA and CTSC that clustered together in all assessed
brain regions (thalamus, cerebellum and medulla ex-
cluded; Fig. 7) within preserved modules indicating im-
mune- and lysosomal-related processes in microglia.
Our data support the idea of a synergistic interplay be-
tween immune system and degradation processes relying
on the activation of immune responses, phagocytosis
and lysis in the lysosomes, particularly through: i) re-
sponse to a stimulus (stress, chemical [interferon-gamma
or cytokine] or biotic stimulus); ii) activation and aggre-
gation of immune (microglial) cells; iii) signal transduc-
tion (mediated by interferon-gamma, cytokine and
antigen receptor [MHC class II protein complexes] and
transducer activities), and; iv) phagocytosis and lyso-
somal processing through endocytic vesicles, phago-
somes, and endolysosomes. Interestingly, a number of
transcripts highly interconnected with both the HLA-
DRA and CTSC also support these processes, and might
be novel functional markers to be further investigated in
the cell-biology setting, such as: CYBB (cytochrome b-
245, beta polypeptide) encodes a critical component of
the oxidase system of phagocytes [37] and DOCK8
(dedicator of cytokinesis 8) encodes a protein involved
in neuronal development [38] and immune cells shaping
[39]. Furthermore, and probably more importantly, we
identified overlap between our transcripts data and pro-
tein interactors of HLA-DRA such as HLA-DMB, HLA-
DMA and CD74 to be considered for further investigation
in the functional environment. These not only appeared to
support immune cell (microglia) activation and maturation,
cell-cell adhesion and MHC class II complex activity, but
also the biology of extracellular vesicles such as exosomes,
and that of lysosomes and lytic vacuoles. These data sup-
port the results of our GWAS [16] and the idea that im-
mune processes and lysosomal biology are important and
likely common elements across different neurodegenerative
diseases [17, 40, 41].
The third biological process was defined by TMEM106B,
C9orf72, VCP, UBQLN2 and OPTN. TMEM106B was ubi-
quitous across all assessed tissues (thalamus, cerebellum
and medulla excluded; Fig. 7) in various brain cell types
(neurons, oligodendrocytes, pyramidal cells) and associated,
from a functional perspective, with various protein
metabolism processes. Particularly, we found that
TMEM106B appears to play a key role in processes sup-
porting protein homeostasis and transport, catabolism
and protein secondary changes involving the ER. Inter-
estingly, our data confirm the importance of these pro-
cesses in neurodegeneration and indicate potential
interactors or targets of TMEM106B among the tran-
scripts highly interconnected with TMEM106B that
should be considered for further investigation in the
cell-biology setting, including: COPB2 (coatomer pro-
tein complex, subunit beta 2, an essential protein for
Golgi budding and vesicular trafficking), SERINC1
(serine incorporator 1, a carrier protein involved in lipid
biosynthesis in neurons at the ER level) [42], NRD1
(nardilysin [N-arginine dibasic convertase], a metallo-
protease with potential neuropathogenic role) [43] and
TTC37 (tetratricopeptide repeat domain 37, a protein-
protein interactor with chaperone activity).
C9orf72, VCP, UBQLN2 and OPTN were relevant in
both the frontal and temporal cortices where they clus-
tered within modules indicating primarily protein cata-
bolic processes; this was also evident for the putamen,
thalamus, hippocampus, cerebellum and medulla (Fig. 7).
It is relevant to note not only that PPIs data strongly
pointed towards ‘protein catabolism’ pathways (mainly
driven by VCP, UBQLN2, OPTN and their associated
PPIs), but also that our transcripts interconnectivity data
indicated further novel potential factors, involved in
catabolic processes and interactors of C9orf72, VCP,
UBQLN2 and OPTN, such as: CAND1 (cullin-associated
and neddylation-dissociated 1), a factor involved in ubi-
quitin ligase network, critical for substrate degradation
[44]; PSMD12 (proteasome 26S subunit, non-ATPase
12) that encodes a subunit of a multi-catalytic proteinase
complex, and; MYCBP2 (MYC binding protein 2, E3
ubiquitin protein ligase) that functions as a E3 ubiquitin
protein ligase. All these factors, such as CAND1,
PSMD12 and MYCBP2 (among the interconnected tran-
scripts) as well as ELAVL1, EIF2B2, CUL2, UBQLN1,
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NF1, NIPSNAP1, BTRC, ARFGEF2, COPS3, PLAA,
CLTA, ANXA7, SEC23A, USP9X, STAM, HSPA13,
RAB11A and RTN3 (co-expressed transcripts and PPIs
of C9orf72, VCP, UBQLN2 and OPTN; see Table 4 for
detailed associations with the spectrum FTD-genes)
should be considered for further investigation in the
functional environment.
Finally, CHMP2B, FUS and TARDBP not only did not
hold major relevance in their respective modules in the
frontal and/or temporal cortex, but also such modules
either contained very small or very large numbers of co-
expressed genes (see Table 2); nevertheless, we assessed
their potential biological meaning through functional an-
notation and pathways analyses (see Additional file 1 pp
4-5 and 7) we found very general (thus negligible) pro-
cesses for CHMP2B, whilst we noted processes mainly
associated with the RNA metabolism for FUS and
TARDBP, confirming their involvement in the modula-
tion of RNA processing [45].
Conclusion
In summary, with this study we further characterize
known FTD-genes by providing insight into their
regional-specific functional networks and associated bio-
logical processes that might be implicated in the patho-
genesis of FTD (Fig. 7). Particularly, we: i) show the
probable involvement of transcription regulation, chro-
matin remodelling and DNA protection through the net-
works of MAPT and GRN; ii) further support the likely
involvement of immune and lysosomal processes
through the networks of CTSC and HLA-DRA, and; iii)
confirm implication of protein meta/catabolism through
the networks of C9orf72, VCP, UBQLN2 and OPTN, and
TMEM106B.
In addition, we also highlight novel potential genetic
and/or functional risk factors (Table 4) to be further ex-
plored in focused and extended hypothesis driven cell
biology work.
As a final remark, our work overall suggests that we
are at a point in time in which there is a critical need for
a shift in the study of complex traits and diseases from a
reductionist ‘gene→ pathology’ type of approach to a
more holistic ‘gene ↔ networks ↔ pathways’ strategy.
Methods
Expression during development and aging across brain
tissues
We assessed expression for FTD-genes in different brain
areas by means of the Human Brain Atlas (HBA; [46])
and Braineac [47, 48]. Data from HBA allow to assess
expression levels in the cerebellar cortex, mediodorsal
nucleus of the thalamus, striatum, amygdala, hippocam-
pus, and 11 areas of the neocortex; data from Braineac
allow to assess expression levels in ten distinct brain
areas such as the frontal cortex, temporal cortex,
putamen, thalamus, hippocampus, white matter, cere-
bellum, medulla, substantia nigra and occipital cortex.
We also extracted expression quantitative trait loci
(eQTL) data from Braineac for further analysis and
characterization of the newly identified potential risk
factors for FTD.
Ethics
Expression data analysed in this study were generated
from 101 control individuals was collected by the Med-
ical Research Council Sudden Death Brain and Tissue
Bank, Edinburgh, UK [48, 49] and are available in
NCBI’s GEO through accession number GSE46706. All
samples had fully informed consent for retrieval and
were authorized for ethically approved scientific investi-
gation (Research Ethics Committee [REC] number 10/
H0716/3).
Weighted gene co-expression network analysis (WGCNA)
Networks were generated by weighted gene co-
expression network analysis (WGCNA) (see [50, 51])
and modules of highly correlated genes were determined
in an unsupervised manner based on co-expression pat-
terns in the ten distinct brain areas: frontal cortex, tem-
poral cortex, putamen, thalamus, hippocampus, white
matter, cerebellum, medulla, substantia nigra and occipi-
tal cortex. Comparatively to previous work (see details
in [17, 52]) we generated networks using 19,152 tran-
scripts. We assessed 14 transcripts corresponding to 12
FTD-genes (MAPT, GRN, CHMP2B, CTSC, HLA-DRA,
TMEM106B, C9orf72, VCP, UBQLN2, OPTN, TARDBP
and FUS; Table 2). HLA-DRB5 was not present in the
Braineac dataset; RAB38, SQSTM1, and BTNL2 were ex-
cluded before network analysis due to preliminary inclu-
sion/exclusion criteria (see [17]), and; FUS had three
transcripts (ID3656904, 3656950, and 3656954). We par-
ticularly focused on frontal and temporal cortex, the
classically affected brain areas in FTD; we also analysed
other brain regions such as the putamen, thalamus,
hippocampus and white matter (pure and spectrum
genes), and the cerebellum and medulla (spectrum genes
only), where the FTD-genes were highly co-expressed or
were hubs. To identify highly interconnected genes
within each module (hubs) we used the measure of mod-
ule membership (MM), a Pearson correlation between
gene-expression level and module-eigengene. An ele-
vated MM (>0.6) suggests strong inter-correlations be-
tween genes in a module. We used the 1-quantile
measure of the MMs to define inter-modular hubs as
any top 10 % gene (i.e. genes with a 1-quantile <0.10).
We evaluated whether modules (containing a minimum
of two FTD-transcripts) were significantly enriched with
FTD-genes using a hypergeometric distribution (with
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Bonferroni correction for multiple testing) and, to valid-
ate modules’ consistency and preservation across tissues,
we calculated a composite Z-summary statistic that
aggregates different module preservation statistics (Z-
summary > 10 =module preservation; Z-summary < 2 = no
preservation) [53].
As transcriptome organization in a given biological
system is highly reproducible [19], we compared the
modules containing FTD-genes to previous WGCNA
studies in human brain, gene-markers for cell types, and
region-enriched or disease-specific genes using the
WGCNA function userListEnrichment [54]. Such lists
are referenced in the Additional file 1 and significant
overlap (Bonferroni corrected) with each FTD-module is
reported in the results section.
Mantel test and construction of replication network
To assess the reproducibility, and thus replicate, the
frontal cortex networks we used the Colantuoni dataset
[18] with GEO accession number GSE30272 (Illumina
Human 49K Oligo array, HEEBO-7 Set). This comprises
269 prefrontal cortex human samples but we restricted
our analysis to 175 (i.e. those with age > 16). We used
the pre-processed/normalized data version of such data-
set. In order to validate the frontal cortex WGCNA net-
works we designed two procedures aiming at evaluating
their reproducibility at two levels.
On the one hand we wanted to assess whether the
WGCNA topological overlap measure (TOM) matrix
from the frontal cortex tissue was significantly repro-
duced in the WGCNA TOM matrix constructed for the
Colauntoni dataset. For such purpose we applied a Man-
tel test [55] with the ape R package, version 3.4: this is a
permutation test that, using two squared matrices of the
same range (i.e. the two TOMs in this case), calculates a
Z-statistic defined as the sum of the pairwise product of
the lower triangles of the permuted TOMs. The test then
compares the permuted distribution with the Z-statistic
observed for the actual data and generates a p-value.
On the other hand, for evaluating the quality of each
frontal cortex network’s module we constructed a signed
WGCNA network on the Colauntoni dataset by using
the same method employed for the construction of the
signed network from our frontal cortex microarray gene
expression profiles with beta value of 11, guaranteeing
scale free topology property. The generated WGCNA
network had 23 modules with sizes between 174 and
2293 genes. As we wanted to assess the level of replica-
tion of our frontal cortex co-expression network on the
Colauntoni et al. network we carried out a preservation
analysis by using the preservation R function imple-
mented by WGCNA software. For that we focused on
the Z-summary preservation estimate which is obtained
by the aggregation of various estimates focused on two
main aspects. On the one hand, estimates on how inter-
action patterns of genes within the modules, as they are
seen in the reference tissue (i.e. in our case our frontal
cortex samples), are preserved in the other tissue (i.e. the
Colauntoni network). On the other hand, it includes as
well clustering estimates which focus on how the genes
which cluster together in the reference tissue maintain
that clustering in the other dataset. The Z preservation
summary is a mean of both estimates. And the estimates
are obtained by a permutation analysis [53].
Gene set enrichment and pathway analysis with g:Profiler
We performed functional annotation and pathways analysis
for the highly co-expressed genes within the FTD-genes
containing modules to characterise their biological rele-
vance assessing GO terms for biological processes (BPs),
cellular components (CCs) and molecular functions (MFs)
by means of the bioinformatics tool gProfiler (accessed in
March and April 2015) [56]. We used the whole set of
19,152 transcripts as a tissue specific background and con-
sidered significant those GO terms with p < 0.05 based on
gProfiler’s custom threshold g:SCS [56].
VisANT visualization
Interconnections between transcripts, defined by topo-
logical overlap measures (TOMs), of relevant modules
containing FTD-genes were visualized using VisANT
[57]. We only showed the strongest interconnected genes
by visualizing TOMs greater than specific thresholds indi-
cated for each module (explained in Figs. 2, 3, 4 and 5). We
limited our analysis to relevant modules (= modules con-
taining one or more FTD-genes with hub status [1-q < 0.1]
and/or module membership [MM] values > 0.5) identified
in frontal cortex.
Protein-protein interaction (PPI) analysis
We searched for currently known protein-protein interac-
tors (PPIs) of the pure and spectrum FTD-genes and com-
pared them with the lists of genes included in the
modules containing FTD-genes identified in the frontal
and temporal cortices. Briefly, a list of protein interactors
associated with each FTD-gene was downloaded from
Biogrid [58], IntAct and MINT [59] databases; such data-
bases provide a constantly updated survey of PPIs based
on manual curation of peer reviewed literature. We then
filtered PPIs manually to remove interactions whose taxid
was non-human. OnIy PPIs whose respective genes were
expressed in the same modules containing the FTD-genes
were considered of relevance based on the convergent evi-
dence that they are: i) expressed in brain; ii) co-expressed
with FTD-genes, and; iii) proven protein interactors of
FTD-genes.
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Additional files
Additional file 1: This file includes additional and complementary
text as well as supplementary figures. (PDF 1444 kb)
Additional file 2: This file includes additional tables to complement
and support the main text. (PDF 18446 kb)
Abbreviations
AD: Alzheimer’s disease; AKT1: V-akt murine thymoma viral oncogene
homolog 1; ALS: amyotrophic lateral sclerosis; ANXA7: annexin A7;
APP: amyloid beta (A4) precursor protein; ARFGEF2: ADP ribosylation factor
guanine nucleotide exchange factor 2; ATN1: atrophin 1; BPs: biological
processes; BTNL2: butyrophilin-Like 2; BTRC: beta-transducin repeat
containing E3 ubiquitin protein ligase; bvFTD: behavioural variant FTD;
C9orf72: chromosome 9 open reading frame 72; CAND1: Cullin-associated
and neddylation-dissociated 1; CCs: cellular components; CD74: CD74
molecule, major histocompatibility complex, class II invariant chain;
CHMP2B: charged multivesicular body protein 2B; CLTA: clathrin, light chain
A; COPB2: coatomer protein complex, subunit beta 2; COPS3: COP9
signalosome subunit 3; CREBBP: CREB binding protein; CRKL: V-crk avian
sarcoma virus CT10 oncogene homolog-like; CTSC: catepsin C; CUL2: Cullin 2;
CYBB: cytochrome b-245, beta polypeptide; DOCK8: dedicator of cytokinesis
8; EIF2B2: eukaryotic translation initiation factor 2B subunit beta;
ELAVL1: ELAV like RNA binding protein 1; EP300: E1A binding protein p300;
ER: endoplasmic reticulum; FCTX: frontal cortex; FTD: frontotemporal
dementia; FTD-17: frontotemporal dementia linked to chromosome 17;
FTD-3: frontotemporal dementia linked to chromosome 3;
FTLD-FUS: frontotemporal lobar degeneration with FUS pathology;
FTLD-tau: frontotemporal lobar degeneration with tau pathology;
FTLD-TDP: frontotemporal lobar degeneration with TDP-43 pathology;
FTLD-UPS: frontotemporal lobar degeneration with p-62
(ubiquitin-proteasome system) pathology; FUS: fused in sarcoma;
GO: gene ontology; GRN: progranulin; GWAS: genome wide association
studies; HCFC1: host cell factor C1; HLA: human leukocyte antigen;
HLA-DMA: major histocompatibility complex, class II, DM alpha;
HLA-DMB: major histocompatibility complex, class II, DM beta;
HLA-DRA: major histocompatibility complex, class II, DR alpha;
HLA-DRB5: major histocompatibility complex, class II, DR beta 5;
HSPA13: heat shock protein family A (Hsp70) member 13;
IBMPFD: inclusion body myopathy with early-onset Paget disease and
frontotemporal dementia; KHSRP: KH-type splicing regulatory protein;
MAPT: microtubule associated protein tau; MARK2: MAP/microtubule
affinity-regulating kinase 2; MARK4: MAP/microtubule affinity-regulating
kinase 4; MFs: molecular functions; MHC: major histocompatibility
complex; MLL2: lysine (K)-specific methyltransferase; MM: module
membership; MS: multiple sclerosis; MYCBP2: MYC binding protein 2,
E3 ubiquitin protein ligase; NF1: neurofibromin 1; NIPSNAP1: nipsnap
homolog 1; NRD1: nardilysin N-arginine dibasic convertase;
OPTN: optinuerin; PBD: Paget’s disease of bone; PLAA: phospholipase
A2-activating protein; PNFA: progressive non-fluent aphasia;
PPIs: protein-protein interactors; PSMD12: proteasome 26S subunit,
non-ATPase 12; RAB11A: RAB11A, member RAS oncogene family;
RAB38: RAB38, member RAS oncogene family; RTN3: reticulon 3;
SD: semantic dementia; SEC23A: Sec23 homolog A, COPII coat complex
component; SERINC1: serine incorporator 1; SF3A1: splicing factor 3a,
subunit 1; SGTA: small glutamine-rich tetratricopeptide repeat
(TPR)-containing, alpha; SQSTM1: sequestosome 1; SRCAP: Snf2-related
CREBBP activator protein; STAM: signal transducing adaptor molecule;
TARDBP: TAR-DNA binding protein 43; TCTX: temporal cortex;
TLE3: transducin-like enhancer of split 3; TMEM106B: transmembrane
protein 106B; TOM: topological overlap measure;
TTC37: tetratricopeptide repeat domain 37; UBQLN1: ubiquilin 1;
UBQLN2: ubiquilin 2; UKBEC: UK human brain expression consortium;
UPS: ubiquitin proteasome system; USP9X: ubiquitin specific peptidase
9, X-linked; VCP: valosin containing protein; WGCNA: weighted gene
co-expression network analysis.
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